The Benefits and Risks of Menopause Hormone Therapy for the Cardiovascular System in Postmenopausal Women: a Systematic Review and Meta-analysis

Overview

Journal BMC Womens Health

Publisher Biomed Central

Specialty Gynecology & Obstetrics

Date 2024 Jan 23

PMID 38263123

Authors

Yimeng Gu

Fangfang Han

Mei Xue

Miyuan Wang

Yuxiao Huang

Affiliations

Soon will be listed here.

Abstract

Background: Menopause hormone therapy (MHT), as an effective method to alleviate the menopause-related symptoms of women, its benefits, risks, and potential influencing factors for the cardiovascular system of postmenopausal women are not very clear.

Objectives: To evaluate cardiovascular benefits and risks of MHT in postmenopausal women, and analyze the underlying factors that affect both.

Search Strategy: The EMBASE, MEDLINE, and CENTRAL databases were searched from 1975 to July 2022.

Selection Criteria: Randomized Clinical Trials (RCTs) that met pre-specified inclusion criteria were included.

Data Collection And Analysis: Two reviewers extracted data independently. A meta-analysis of random effects was used to analyze data.

Main Results: This systematic review identified 33 RCTs using MHT involving 44,639 postmenopausal women with a mean age of 60.3 (range 48 to 72 years). There was no significant difference between MHT and placebo (or no treatment) in all-cause death (RR = 0.96, 95%CI 0.85 to 1.09, I = 14%) and cardiovascular events (RR = 0.97, 95%CI 0.82 to 1.14, I = 38%) in the overall population of postmenopausal women. However, MHT would increase the risk of stroke (RR = 1.23, 95%CI 1.08 to 1.41,I = 0%) and venous thromboembolism (RR = 1.86, 95%CI 1.39 to 2.50, I = 24%). Compared with placebo, MHT could improve flow-mediated arterial dilation (FMD) (SMD = 1.46, 95%CI 0.86 to 2.07, I = 90%), but it did not improve nitroglycerin-mediated arterial dilation (NMD) (SMD = 0.27, 95%CI - 0.08 to 0.62, I = 76%). Compared with women started MHT more than 10 years after menopause, women started MHT within 10 years after menopause had lower frequency of all-cause death (P = 0.02) and cardiovascular events (P = 0.002), and more significant improvement in FMD (P = 0.0003). Compared to mono-estrogen therapy, the combination therapy of estrogen and progesterone would not alter the outcomes of endpoint event. (all-cause death P = 0.52, cardiovascular events P = 0.90, stroke P = 0.85, venous thromboembolism P = 0.33, FMD P = 0.46, NMD P = 0.27).

Conclusions: MHT improves flow-mediated arterial dilation (FMD) but fails to lower the risk of all-cause death and cardiovascular events, and increases the risk of stroke and venous thrombosis in postmenopausal women. Early acceptance of MHT not only reduces the risk of all-cause death and cardiovascular events but also further improves FMD, although the risk of stroke and venous thrombosis is not reduced. There is no difference in the outcome of cardiovascular system endpoints between mono-estrogen therapy and combination therapy of estrogen and progesterone.

Citing Articles

Impact of Estrogen on Purinergic Signaling in Microvascular Disease.

Cassavaugh J, Longhi M, Robson S Int J Mol Sci. 2025; 26(5).

PMID: 40076726 PMC: 11900469. DOI: 10.3390/ijms26052105.

Sleep and Brain Function at Menopause.

Garg R, Munshi A J Midlife Health. 2025; 15(4):221-224.

PMID: 39959736 PMC: 11824937. DOI: 10.4103/jmh.jmh_201_24.

Bilateral lower extremity amputation in a transgender female on estrogen therapy suffering from recurrent, medication-resistant arterial thrombi.

McDaniels M, Conroy P, Batista P J Vasc Surg Cases Innov Tech. 2024; 11(1):101655.

PMID: 39659823 PMC: 11629560. DOI: 10.1016/j.jvscit.2024.101655.

Effect of Isoflavone on Muscle Atrophy in Ovariectomized Mice.

Kawai S, Okamura T, Munekawa C, Hasegawa Y, Kobayashi A, Nakajima H Nutrients. 2024; 16(19).

PMID: 39408262 PMC: 11478932. DOI: 10.3390/nu16193295.

References

Blumel J, Castelo-Branco C, Leal T, Gallardo L, Saini J, Ferron S . Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric. 2003; 6(1):38-44. View

Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F . Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol. 2001; 21(9):1512-9. DOI: 10.1161/hq0901.095565. View

Herrington D, Reboussin D, Brosnihan K, Sharp P, Shumaker S, Snyder T . Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000; 343(8):522-9. DOI: 10.1056/NEJM200008243430801. View

Casanova G, Ramos R, Ziegelmann P, Spritzer P . Effects of low-dose versus placebo or conventional-dose postmenopausal hormone therapy on variables related to cardiovascular risk: a systematic review and meta-analyses of randomized clinical trials. J Clin Endocrinol Metab. 2014; 100(3):1028-37. DOI: 10.1210/jc.2014-3301. View

Sherwood A, Bower J, McFetridge-Durdle J, Blumenthal J, Newby L, Hinderliter A . Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler Thromb Vasc Biol. 2007; 27(8):1782-7. DOI: 10.1161/ATVBAHA.107.145383. View

Sahebkar A . Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res. 2013; 28(5):633-42. DOI: 10.1002/ptr.5045. View

Ouyang P, Tardif J, Herrington D, Stewart K, Thompson P, Walsh M . Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis. 2006; 189(2):375-86. DOI: 10.1016/j.atherosclerosis.2005.12.015. View

Viscoli C, Brass L, Kernan W, Sarrel P, Suissa S, Horwitz R . A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001; 345(17):1243-9. DOI: 10.1056/NEJMoa010534. View

Hendrix S, Wassertheil-Smoller S, Johnson K, Howard B, Kooperberg C, Rossouw J . Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006; 113(20):2425-34. DOI: 10.1161/CIRCULATIONAHA.105.594077. View

10.

Greendale G, Lee N, Arriola E . The menopause. Lancet. 1999; 353(9152):571-80. DOI: 10.1016/S0140-6736(98)05352-5. View

11.

Veerus P, Hovi S, Fischer K, Rahu M, Hakama M, Hemminki E . Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas. 2006; 55(2):162-73. DOI: 10.1016/j.maturitas.2006.01.012. View

12.

Kelemen M, Vaidya D, Waters D, Howard B, Cobb F, Younes N . Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. Atherosclerosis. 2005; 179(1):193-200. DOI: 10.1016/j.atherosclerosis.2004.09.021. View

13.

Martin J, Kristensen S, Mathur A, Grove E, Choudry F . The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol. 2012; 9(11):658-70. DOI: 10.1038/nrcardio.2012.131. View

14.

Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K, Fukaya T . Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol. 2003; 24(3):571-6. DOI: 10.1161/01.ATV.0000115383.49802.0c. View

15.

Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset P . Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2001; 84(6):961-7. View

16.

Guyot P, Ades A, Ouwens M, Welton N . Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9. PMC: 3313891. DOI: 10.1186/1471-2288-12-9. View

17.

Gordon J, Rubinow D, Watkins L, Hinderliter A, Caughey M, Girdler S . The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease. J Clin Endocrinol Metab. 2019; 105(5). PMC: 7096310. DOI: 10.1210/clinem/dgz262. View

18.

Sahebkar A, Serban M, Penson P, Gurban C, Ursoniu S, Toth P . The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. Drugs. 2017; 77(11):1187-1197. PMC: 5501893. DOI: 10.1007/s40265-017-0767-4. View

19.

. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7):728-753. DOI: 10.1097/GME.0000000000000921. View

20.

Wessler S . Estrogen-associated thromboembolism. Ann Epidemiol. 1992; 2(4):439-43. DOI: 10.1016/1047-2797(92)90093-6. View